Clik here to view.
Review of SURPASS-ET Trial Evaluating Ropeginterferon Alfa-2b-njft for...
BURLINGTON, Mass. PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven...
View ArticleClik here to view.
HERTHENA-Lung02 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients...
TOKYO & BASKING RIDGE, N.J. Daiichi Sankyo (TSE: 4568) announced today that the first patient has been dosed in the global HERTHENA-Lung02 phase 3 trial evaluating the efficacy and safety of...
View ArticleClik here to view.
Cyclo Therapeutics to Present at the China NPC Association Meeting
GAINESVILLE, Fla. Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through...
View ArticleClik here to view.
Datopotamab Deruxtecan-Based Combinations Show Promising Clinical Activity in...
TOKYO & BASKING RIDGE, N.J. Initial results from the TROPION-Lung02 phase 1b trial showed that datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum...
View ArticleClik here to view.
2022 International Symposium on Human Identification (ISHI) Keynote DeNeen L....
MADISON, Wis. More than 1000 forensic DNA experts and law enforcement professionals from around the world will gather at the International Symposium on Human Identification (ISHI) October 31 –...
View ArticleClik here to view.
Cellworks Singula™ TRI Provides Superior OS Predictions for NSCLC Patients...
SOUTH SAN FRANCISCO, Calif. Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-203A...
View ArticleClik here to view.
Cullgen Announces Chinese NMPA Allowance of Investigational New Drug...
SAN DIEGO Cullgen Inc., a leading biotechnology company developing targeted protein degraders based on its proprietary uSMITE™ platform technology, today announced that the Chinese National Medical...
View ArticleClik here to view.
Clik here to view.
Clik here to view.
ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients...
TOKYO & BASKING RIDGE, N.J. Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of adult...
View ArticleClik here to view.
InnoCare Announces Acceptance of Supplemental New Drug Application for...
BEIJING InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of the China...
View ArticleClik here to view.
Arbitrator Rules in Favor of Daiichi Sankyo in Dispute with Seagen
TOKYO & MUNICH & BASKING RIDGE, N.J. An arbitrator issued a decision today in a dispute between Daiichi Sankyo Company, Ltd. and Seagen, Inc., denying all claims made by Seagen....
View ArticleClik here to view.
ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase...
TOKYO & MUNICH & BASKING RIDGE, N.J. Positive topline results from the DESTINY-Breast02 phase 3 trial of ENHERTU® (trastuzumab deruxtecan) versus physician’s choice of treatment showed the...
View ArticleClik here to view.
BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community...
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company that is developing and commercializing innovative and...
View ArticleClik here to view.
EpiAxis Therapeutics ＆ Peptilogics Enter Strategic Drug Discovery Partnership
SYDNEY & PITTSBURGH EpiAxis Therapeutics, a leading epigenetics company with a focus on the treatment, diagnosis and monitoring of cancer and the prevention of its recurrence, and Peptilogics, a...
View ArticleClik here to view.
Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI...
DANVERS, Mass. Abiomed (Nasdaq: ABMD) announces the results of the Restore EF study demonstrate Impella-supported high-risk percutaneous coronary intervention (PCI) leads to significant improvements...
View ArticleClik here to view.
Genexine Announces Dosing of First Patient in Phase 2 clinical trial with...
SEOUL, South Korea Genexine (KOSDAQ: 095700), a publicly traded, clinical-staged Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of...
View ArticleClik here to view.
Exscientia Business Update for Second Quarter and First Half 2022
OXFORD, England Exscientia plc (Nasdaq: EXAI) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220817005681/en/ Recent developments in the...
View ArticleClik here to view.
Restore EF試験で、Impella補助による高リスクPCI患者の心機能および症状改善を確認
米マサチューセッツ州ダンバース （ビジネスワイヤ） — アビオメッド(Nasdaq: ABMD)は、 Restore...
View ArticleClik here to view.
Publication in Nature Molecular Psychiatry Supports Genuv’s Alternate Theory...
SEOUL, Republic of Korea Genuv Inc., a clinical-stage biotechnology company focused on innovative drug discovery for central nervous system disorders and advanced antibody therapies for...
View Article